GlassScriptPhysician profile
Donna L Pryor
NPI 1639145386
$3,675.56
in general payments reported to CMS, 2019-2025
26 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 90% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $696 · 2022: $682 · 2023: $712 · 2024: $546 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,297.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $724.37 | 2021-2025 | |
| Incyte Corporation | $490.74 | 2021-2025 | Opzelura, Iclusig |
| Janssen Biotech, INC. | $469.57 | 2021-2025 | Tremfya, Stelara, Simponi |
| Sun Pharmaceutical Industries INC. | $316.92 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $209.43 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $203.33 | 2021-2025 | Dupixent |
| Genzyme Corporation | $200.87 | 2021-2023 | |
| Pfizer INC. | $169.98 | 2021 | |
| Amgen INC. | $154.51 | 2021-2024 | Otezla |
| Lilly USA, LLC | $122.08 | 2021-2025 | Taltz, Zepbound, Ebglyss |
| Galderma Laboratories, L.P. | $95.09 | 2021-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $68.20 | 2024-2025 | Sotyktu |
| Strata Skin Sciences, INC. | $53.45 | 2024-2025 | Xtrac |
| Ucb, INC. | $49.52 | 2025 | Bimzelx |
| Genentech USA, INC. | $48.10 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgenex LLC | $40.09 | 2025 | Surgraft, Ardeograft, Renograft |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.84 | 2023 | Spevigo |
| Arcutis Biotherapeutics, INC. | $32.74 | 2023-2025 | Zoryve |
| Almirall LLC | $31.62 | 2025 | Klisyri |
| Misonix INC | $30.99 | 2021 | |
| Dermavant Sciences, INC. | $26.18 | 2023 | Vtama |
| Leo Pharma INC. | $25.04 | 2024 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.00 | 2021 | |
| Organon LLC | $22.78 | 2025 | Vtama |
| Merz North America, INC. | $16.82 | 2021 | |
| Sandoz INC. | $16.30 | 2025 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Pryor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.